Published in J Vis Exp on October 18, 2013
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature (2015) 1.65
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature (2014) 1.61
Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol (2015) 1.51
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet (2014) 1.34
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med (2014) 1.18
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today (2015) 1.12
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun (2015) 1.07
NF1 Mutations Are Common in Desmoplastic Melanoma. Am J Surg Pathol (2015) 1.04
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol (2014) 1.01
Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol (2016) 1.00
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discov (2015) 0.98
GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. J Am Coll Surg (2015) 0.93
Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol (2015) 0.87
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov (2015) 0.86
Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight (2016) 0.82
Advancing clinical oncology through genome biology and technology. Genome Biol (2014) 0.81
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer (2016) 0.81
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies. J Vis Exp (2016) 0.81
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod Pathol (2016) 0.80
The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol (2016) 0.79
EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. Pancreatology (2015) 0.79
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet (2016) 0.79
Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. Genes Chromosomes Cancer (2015) 0.78
Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. Cancer Res (2015) 0.78
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun (2016) 0.77
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clin Cancer Res (2015) 0.77
Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. Cancer Cytopathol (2015) 0.77
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nat Commun (2017) 0.75
Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. J Oncol Pract (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet (2009) 58.77
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
The cancer genome. Nature (2009) 23.13
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Target-enrichment strategies for next-generation sequencing. Nat Methods (2010) 8.78
Dindel: accurate indel calls from short-read data. Genome Res (2010) 8.62
Identification of genetic variants using bar-coded multiplexed sequencing. Nat Methods (2008) 7.50
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics (2011) 5.62
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics (2012) 5.04
A geometric approach for classification and comparison of structural variants. Bioinformatics (2009) 2.79
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res (2012) 1.82
SOAPindel: efficient identification of indels from short paired reads. Genome Res (2012) 1.59
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Clinical cancer genomics: how soon is now? J Pathol (2010) 1.01
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Diversity and complexity in DNA recognition by transcription factors. Science (2009) 9.07
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays. Nat Genet (2004) 6.33
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
High-resolution DNA-binding specificity analysis of yeast transcription factors. Genome Res (2009) 5.11
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J (2010) 4.78
Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol (2009) 2.65
The Vibrio harveyi master quorum-sensing regulator, LuxR, a TetR-type protein is both an activator and a repressor: DNA recognition and binding specificity at target promoters. Mol Microbiol (2008) 2.11
Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res (2009) 1.97
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell (2016) 1.79
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76
Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae. Genome Res (2007) 1.75
Microarray analyses of newborn mouse ovaries lacking Nobox. Biol Reprod (2007) 1.67
Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol (2014) 1.60
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55
Design of compact, universal DNA microarrays for protein binding microarray experiments. J Comput Biol (2008) 1.45
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest (2016) 1.36
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res (2013) 1.34
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res (2013) 1.31
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov (2014) 1.25
Basic research in kidney cancer. Eur Urol (2011) 1.19
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
Inferring condition-specific transcription factor function from DNA binding and gene expression data. Mol Syst Biol (2007) 1.13
Molecular mechanism underlying the regulatory specificity of a Drosophila homeodomain protein that specifies myoblast identity. Development (2012) 1.05
NF1 Mutations Are Common in Desmoplastic Melanoma. Am J Surg Pathol (2015) 1.04
Conservation and regulatory associations of a wide affinity range of mouse transcription factor binding sites. Genomics (2010) 1.02
Predicting the binding preference of transcription factors to individual DNA k-mers. Bioinformatics (2008) 1.01
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol (2014) 1.01
Notch and MAML-1 complexation do not detectably alter the DNA binding specificity of the transcription factor CSL. PLoS One (2010) 0.93
"N of 1" case reports in the era of whole-genome sequencing. J Clin Invest (2013) 0.90
Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol (2015) 0.87
Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. J Thorac Oncol (2015) 0.82
Advancing clinical oncology through genome biology and technology. Genome Biol (2014) 0.81
Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol (2014) 0.81
Basal cell carcinosarcoma with PTCH1 mutations in both epithelial and sarcomatoid primary tumor components and in the sarcomatoid metastasis. Am J Surg Pathol (2014) 0.80
Objective sequence-based subfamily classifications of mouse homeodomains reflect their in vitro DNA-binding preferences. Nucleic Acids Res (2010) 0.78
Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. J Pediatr Hematol Oncol (2016) 0.75
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med (2017) 0.75
Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. J Pediatr Hematol Oncol (2017) 0.75
Combined melanocytic and sweat gland neoplasm: cell subsets harbor an identical HRAS mutation in phacomatosis pigmentokeratotica. J Cutan Pathol (2014) 0.75